Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Evaluating the utility of adult-defined prognostic biomarkers in childhood onset primary chronic vasculitis
FY 2022-23
Summary
Our research team is committed to improving the lives of children with a rare disease called “vasculitis”. Until recently, vasculitis was fatal for most children within one year of diagnosis. Newer treatments have been lifesaving but may cause serious infections, cancer, and difficulty (as adults) having children. Because of this, giving drugs at high doses and/or over a long time should be reserved for kids with stubborn disease that won’t stay in remission and/or kids with aggressive disease in the kidneys. The problem is that it is nearly impossible to identify these children before it’s too late. In people that get vasculitis later in life (> 50 yrs), however, doctors have found ‘markers’ in the blood and urine that tell them who is likely to have stubborn disease and/or kidney failure. It is not known if these markers can provide the same valuable information in children.
In this project, I will check if these ‘adult markers’ can identify the children with the highest risk of getting very bad disease that needs more therapy (high dose or longer use of drug) versus children with milder disease (less drug and for a shorter time). Vasculitis affects so few children (~ 1 child out of every 250,000) that many research studies are nearly impossible. This project is possible due to the work done by doctors and scientists at the BC Children’s Hospital over the past 10+ years to collect data from more than 300 children with vasculitis. If our study shows that any of the tested markers can identify children at risk of getting especially bad disease, this will help improve the lives of these children through better treatment decisions.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
485919
Name
Mann Simranpreet K
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the utility of adult-defined prognostic biomarkers in childhood onset primary chronic vasculitis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoantibodies; Kidneys; Myeloperoxidase; Pediatric Vasculitis; Proteinase-3
Abstract
Our research team is committed to improving the lives of children with a rare disease called “vasculitis”. Until recently, vasculitis was fatal for most children within one year of diagnosis. Newer treatments have been lifesaving but may cause serious infections, cancer, and difficulty (as adults) having children. Because of this, giving drugs at high doses and/or over a long time should be reserved for kids with stubborn disease that won’t stay in remission and/or kids with aggressive disease in the kidneys. The problem is that it is nearly impossible to identify these children before it’s too late. In people that get vasculitis later in life (> 50 yrs), however, doctors have found ‘markers’ in the blood and urine that tell them who is likely to have stubborn disease and/or kidney failure. It is not known if these markers can provide the same valuable information in children.
In this project, I will check if these ‘adult markers’ can identify the children with the highest risk of getting very bad disease that needs more therapy (high dose or longer use of drug) versus children with milder disease (less drug and for a shorter time). Vasculitis affects so few children (~ 1 child out of every 250,000) that many research studies are nearly impossible. This project is possible due to the work done by doctors and scientists at the BC Children’s Hospital over the past 10+ years to collect data from more than 300 children with vasculitis. If our study shows that any of the tested markers can identify children at risk of getting especially bad disease, this will help improve the lives of these children through better treatment decisions.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mann, Simranpreet K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~